Oncology Companion Diagnostic Market To Reach $8.38 Billion By 2030

Oncology Companion Diagnostic Market Growth & Trends

The global oncology companion diagnostic market size is expected to reach USD 8.38 billion by 2030, expanding at a CAGR of 9.02% from 2025 to 2030, according to a new report by Grand View Research, Inc. Expanding access to important genomic information with the aid of companion diagnostics enables informed decision making for designing the targeted treatment approaches for their patients, thereby increasing demand for comprehensive genomic testing and oncology companion diagnostics.

The commercial launch of drugs including Gleevec (imatinib) and Herceptin (trastuzumab) that require Companion Diagnostics (CDx) testing before prescription has increased revenue generation in the oncology companion diagnostics field. This growth is expected to continue in the future owing to a substantial number of CDx associated oncology drugs in clinical trials. Apart from functioning as exclusive or inclusive tests for therapies, CDx also plays a crucial role during participant selection in clinical trials. This is because there is an increased potential for a novel drug candidate to show a better response rate if the patient has its biomarker target.

The economic incentives associated with the use of CDx have encouraged drug developers to combine their drugs with diagnostic tests. However, the diagnostic manufacturers face conflicting demands from payers/providers on one hand and drug manufacturers on the other hand. The regulatory bodies also have stringent policies to align the development timelines of diagnostics and drugs. Therefore, the diagnostic companies are expected to broaden their scope of CDx development instead of focusing on the attainment of a match between a single diagnostic with a specific drug.

 Request a free sample copy or view report summary: Oncology Companion Diagnostic Market Report

Oncology Companion Diagnostic Market Report Highlights

• The products segment dominated the market with a share of 66.14% in 2024, driven by advancements in personalized medicine and the increasing prevalence of cancer and the services segment is expected to register the fastest CAGR during the forecast period

• The Polymerase Chain Reaction (PCR) segment dominated the market with a share of 28.03% in 2024 and the next-generation Sequencing (NGS) segment is expected to register the fastest CAGR during the forecast period

• The non-small cell lung cancer segment dominated the market, with a share of 30.32% in 2024 and the breast cancer segment is expected to register the fastest CAGR of 9.65% during the forecast period

• In 2024, North America dominated the overall neuroprosthetics market at over 40.17% owing to the large presence of neural implants manufacturers, higher R&D investments, and the availability of funds from both government and private institutes. For instance, the Defense Advanced Research Project Agency (DARPA) and National Institute of Neurological Disorders and Stroke (NIH)in collaboration with the federal agencies are instrumental in providing funds to support R&D initiatives for the further development of neural implants.

• Asia Pacific is anticipated to be the fastest growing segment due to the introduction of multinational healthcare establishments promoting safe and effective medical procedures along with the rising awareness levels amongst consumers.

• Strategic collaborations and mergers & acquisitions are expected to keep the industry rivalry level high over the forecast period.

Oncology Companion Diagnostic Market Segmentation

Grand View Research has segmented the global oncology companion diagnostic market report based on product & services, technology, disease type, end use, and region

Oncology Companion Diagnostic Product & Services Outlook (Revenue, USD Million, 2018 - 2030)

• Product

  • Instrument

  • Consumables

  • Software

• Services

Oncology Companion Diagnostic Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Polymerase Chain Reaction (PCR)

• Next-generation Sequencing (NGS)

• Immunohistochemistry (IHC)

• In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH)

• Other Technologies

Oncology Companion Diagnostic Disease Type Outlook (Revenue, USD Million, 2018 - 2030)

• Breast Cancer

• Non-small Cell Lung Cancer

• Colorectal Cancer

• Leukemia

• Melanoma

• Prostate Cancer

• Others

Oncology Companion Diagnostic End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital

• Pathology/Diagnostic Laboratory

• Academic Medical Center

Oncology Companion Diagnostic Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Oncology Companion Diagnostic Market

• Agilent Technologies, Inc.

• Illumina, Inc.

• QIAGEN

• Thermo Fisher Scientific Inc.

• Foundation Medicine, Inc.

• Myriad Genetics, Inc.

• F. Hoffmann-La Roche Ltd

• BIOMÉRIEUX

• Abbott

• Leica Biosystems Nussloch GmbH

• Guardant Health

• EntroGen, Inc.